Cubist Pharma CEO Bonney will step down Dec. 31

Published



NEW YORK (AP) — Antibiotic maker Cubist Pharmaceuticals said Monday that Michael Bonney will retire as CEO at the end of the year, and the company said it will promote President Robert Perez to take his place.

Bonney will retire as CEO on Dec. 31, and Perez will be promoted the next day. The company said Bonney will become non-executive chairman of its board of directors. Current Chairman Kenneth Bate will become Cubist’s lead independent director.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.